CD34 and dilated cardiomyopathy: The recently completed repetitive intramyocardial CD34+ cell therapy in dilated cardiomyopathy study (REMEDIUM study) evaluated the potential benefits of repetitive transendocardial CD34+ cell therapy in DCMP patients.